Among psychotropic medications, there are several drug substrates for CYP2D6, including atomoxetine (attention deficit hyperactivity disorder medication) and clozapine (antipsychotic for treatment of schizophrenia), for which drug labels recommend dose adjustments for patients who are CYP2D6 poor metabolizers [40]. The gene discussed is CYP2D6; the disease is attention deficit-hyperactivity disorder.